The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Additionally, Eli Lilly's weight-loss drug gains FDA approval for sleep apnea, amidst growing competition from licensed drug ...

Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...

The pharmaceutical industry faces significant challenges as Novo Nordisk and Eli Lilly grapple with trial setbacks and market ...

The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The Food and Drug Administration (FDA) has recently approved an innovative obesity medication from Eli Lilly that hold ...

The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.

The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...